Publications by authors named "K Zajda"
Article Synopsis
- The study investigated the impact of venous thromboembolic events (VTE) on overall survival in patients with ALK-positive lung cancer who received treatment with ALK inhibitors.
- A total of 54 patients were analyzed, finding that 22.2% experienced VTE, which significantly reduced their overall survival compared to those without VTE (median of 11.7 vs. 37.4 months).
- The findings highlighted that active treatment with certain ALK inhibitors, as well as specific clinical factors like liver metastases and higher leukocyte counts, increased the risk of VTE and negatively affected patient survival.
Background And Purpose: Pulmonary hypertension (PH) results from pulmonary vasculopathy, initially leading to a compensatory right ventricular (RV) hypertrophy, and eventually to RV failure. Hypoxia can trigger both pulmonary vasculopathy and RV failure. Therefore, we tested if myo-inositol trispyrophosphate (ITPP), which facilitates oxygen dissociation from haemoglobin, can relieve pulmonary vasculopathy and RV hypoxia, and eventually prevent RV failure and mortality in the rat model of monocrotaline-induced PH.
View Article and Find Full Text PDFArticle Synopsis
- Right ventricular (RV) function is crucial for the prognosis of patients with pulmonary arterial hypertension (PAH), where the RV initially adapts to increased workload but can ultimately fail.
- The shift from compensated RV hypertrophy to decompensated RV failure is not well understood, and current treatments for RV failure are lacking, as those developed for left ventricular (LV) failure do not work for the RV.
- This paper explores how oxygen delivery and hypoxia may drive RV hypertrophy and failure in PAH, highlighting the need for new therapies by understanding the differences in RV and LV physiology.
Background: The efficacy of nivolumab and atezolizumab in advanced pre-treated NSCLC was documented in prospective trials. We aim to confirm the benefits and indicate predictive factors for immunotherapy in daily practice.
Methods: This study was a retrospective analysis.
The study was conducted in the era when maintenance immunotherapy with durvalumab was not available in clinical practice after chemoradiotherapy (CRT) in unresectable non-small-cell lung cancer (NSCLC). The main aim of the study was to check whether the presence of cardiovascular diseases (CVD) and their pharmacotherapy affects the overall survival (OS) in such NSCLC patients undergoing sequential CRT. The group of 196 patients were analyzed: 101 patients with CVD (51.
View Article and Find Full Text PDF